• FDA Approves Rituximab for Multiple Pediatric Cancers

    1 month ago - By Medscape

    The Food and Drug Administration approved rituximab in combination with chemotherapy for the treatment of pediatric patients with 4 different types of previously untreated, advanced stage blood cancers.
    FDA Approvals
    Read more ...

     

  • FDA approves Rituxan plus chemotherapy for pediatric lymphoma, leukemia

    FDA approves Rituxan plus chemotherapy for pediatric lymphoma, leukemia

    1 month ago - By Healio

    The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.
    The approval applies to use of the regimen for patients aged 6 months to 18 years with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia.
    Rituximab , a chimeric monoclonal antibody that targets CD20, is approved in the United States for multiple cancer indications.
    The FDA based the new indications on results of the randomized Inter-B-NHL Ritux 2010 trial, which
    Read more ...